|Bid||562.00 x 800|
|Ask||576.00 x 1100|
|Day's range||565.39 - 573.01|
|52-week range||441.00 - 686.62|
|Beta (5Y monthly)||0.21|
|PE ratio (TTM)||10.34|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Dr. Calvin Sun, The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.
Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.